Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Basic) (2016 - 2025)

Adma Biologics' EPS (Basic) history spans 14 years, with the latest figure at $0.21 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 56.25% year-over-year to $0.21; the TTM value through Dec 2025 reached $0.61, down 28.24%, while the annual FY2025 figure was $0.62, 27.06% down from the prior year.
  • EPS (Basic) reached $0.21 in Q4 2025 per ADMA's latest filing, up from $0.15 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.48 in Q4 2024 to a low of -$0.16 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.02, with a median of -$0.03 recorded in 2023.
  • Peak YoY movement for EPS (Basic): soared 1400.0% in 2024, then tumbled 56.25% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.07 in 2021, then grew by 14.29% to -$0.06 in 2022, then tumbled by 33.33% to -$0.08 in 2023, then surged by 700.0% to $0.48 in 2024, then tumbled by 56.25% to $0.21 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's EPS (Basic) are $0.21 (Q4 2025), $0.15 (Q3 2025), and $0.14 (Q2 2025).